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There is evidence for iron dysregulation in many forms of disease, including a broad
spectrum of neurodegenerative disorders. In order to advance our understanding of the
pathophysiological role of iron, it is helpful to be able to determine in detail the distribution
of iron as it relates to metabolites, proteins, cells, and tissues, the chemical state and
local environment of iron, and its relationship with other metal elements. Synchrotron light
sources, providing primarily X-ray beams accompanied by access to longer wavelengths
such as infra-red, are an outstanding tool for multi-modal non-destructive analysis of iron in
these systems.Themicro- and nano-focused X-ray beams that are generated at synchrotron
facilities enable measurement of iron and other transition metal elements to be performed
with outstanding analytic sensitivity and speciﬁcity. Recent developments have increased
the scope for methods such as X-ray ﬂuorescence mapping to be used quantitatively
rather than semi-quantitatively. Burgeoning interest, coupled with technical advances and
beamline development at synchrotron facilities, has led to substantial improvements in
resources and methodologies in the ﬁeld over the past decade. In this paper we will
consider how the ﬁeld has evolved with regard to the study of iron in proteins, cells, and
brain tissue, and identify challenges in sample preparation and analysis. Selected examples
will be used to illustrate the contribution, and future potential, of synchrotron X-ray analysis
for the characterization of iron in model systems exhibiting iron dysregulation, and for
human cases of neurodegenerative disorders including Alzheimer’s disease, Parkinson’s
disease, Friedreich’s ataxia, and amyotrophic lateral sclerosis.
Keywords: iron, synchrotron X-rays, human brain,Alzheimer’s disease, Parkinson’s disease, neuromelanin, amyloid
aggregation, magnetic resonance imaging
INTRODUCTION
The study of iron in neurodegenerative disorders emerged a
century ago, arguably catalyzed by developments in histological
methods to demonstrate iron in tissue, and by observations of
abundant iron deposition in the human brain in health and dis-
ease. Lhermitte et al. (1924) describe a Parkinson’s disease (PD)
case with diminished intracellular iron and iron-rich deposits
(“globules”) in the globus pallidus (GP), and with iron in the
substantia nigra (SN) apparently unaltered. Yet on the 90th
anniversary of this paper, as we see evidence that iron chela-
tion can modify brain iron with beneﬁcial effects for PD patients
(Devos et al., 2014), there remain open questions and continuing
debate about the precise nature and consequence of iron dys-
regulation in PD (Gerlach et al., 1994; Galazka-Friedman et al.,
1996; Oakley et al., 2007; Friedman et al., 2009; Crichton et al.,
2011; Visanji et al., 2013). Similar questions about the patho-
physiology of iron arise in many neurodegenerative disorders
including multiple system atrophy (MSA; Visanji et al., 2013),
Alzheimer’s disease (AD; Smith et al., 2010), Huntington’s disease,
Friedreich’s Ataxia, and motor neuron disease (MND) includ-
ing amyotrophic lateral sclerosis (ALS). The extensive evidence
for poorly liganded iron contributing to the pathophysiology
of neurodegenerative disorders is reviewed elsewhere (Kell,
2010).
Disruptions to normal iron homeostasis can exacerbate delete-
rious excess formation of radical species (Kell, 2010), and changes
in regional or cellular iron concentration, or in the proteins
responsible for tightly regulating iron metabolism, may indi-
cate vulnerability to oxidative stress damage that is observed
in the pathophysiology of neurodegenerative disorders (Smith
and Perry, 1995; Castellani et al., 2007; Rouault, 2013). Aber-
rant peptide aggregation leads to the formation of pathological
hallmarks of neurodegenerative disorders such as the beta amy-
loid (Aβ)-rich plaques in AD, and the alpha (α-)synuclein-rich
Lewy bodies in PD. Iron has long been implicated in mecha-
nisms of toxicity associated with aberrant peptide aggregation
(Rottkamp et al., 2001), although work to determine a pre-
cise role for iron is ongoing (House et al., 2004; Everett et al.,
2014a). The reductase behavior of the Aβ and α-synuclein pep-
tides has been shown in vitro (Khan et al., 2006; Davies et al.,
2011). The chemical reduction of ferrihydrite (iron oxide) par-
ticles by Aβ42 has also now been demonstrated in vitro (Everett
et al., 2014a). The contribution of synchrotron X-ray analysis
to such studies, and to understanding fundamental structural
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and conformational properties of the peptides, will be consid-
ered here.
The use of X-rays to study iron in human tissue, and pro-
teins responsible for iron homeostasis, is well-established. For
example, X-ray ﬂuorescence (XRF) spectroscopy was used in
1968 to evaluate iron content in formalin-ﬁxed tissues (Earle,
1968). The use of X-rays for metallomics-related research has
been advanced by the design and development of synchrotron
facilities: particle accelerators with a cyclical path that gen-
erate intense beams of light primarily in the X-ray region
of the electromagnetic spectrum. The ﬁrst synchrotrons were
designed in the 1940s, and subsequently built as large-scale facil-
ities that over several generations of development have enabled
exceptionally diverse and cutting-edge research. In the past
two decades there has been signiﬁcant progress in improv-
ing beam focusing and detectors, facilitating chemical element
imaging and analysis at micro- and nanometer spatial resolu-
tion using techniques such as synchrotron XRF (SXRF) and
X-ray absorption near edge spectroscopy (XANES). There has
also been progress in developing techniques to analyze pro-
teins and protein–metal interactions including high-throughput
crystal structure analysis of proteins, advancing methods to
observe conformational changes to proteins as a function of
temperature and pH, for example, and techniques permitting
time-resolved analysis of these processes (Duke and Johnson,
2010).
Perspectives on developments over the past decade are given
in several reviews of methods for the spatial analysis of metals
in biological tissues: these consider both stand-alone labora-
tory instruments and large shared facilities including neutron
spallation and synchrotron light sources. Lobinski et al. (2006)
reviewed various methods for the analysis of trace metals in
biological environments, noting how technical advances such
as nanoﬂow chromatography enabled work with signiﬁcantly
smaller sample volumes, and how improvements in the deliv-
ery of focused synchrotron beams signiﬁcantly increased scope
to analyze the local chemical environment of metal ions with
X-ray absorption spectroscopy (XAS). Synchrotron methods
including Fourier transform infrared (FTIR) micro-spectroscopy
and imaging (Miller and Dumas, 2006), scanning transmission
X-ray microscopy (STXM; Obst and Schmid, 2014), and SXRF
microscopy (Ralle and Lutsenko, 2009) have been considered,
while Jackson reviewed the stand-alone technique of laser abla-
tion inductively coupled plasma mass spectrometry (LA-ICP-MS)
for transitionmetal element analysis in rodent brain (Jackson et al.,
2006), and Qin et al. (2011) compared SXRF microscopy with LA-
ICP-MS and secondary ion mass spectrometry (SIMS). Notably,
McRae et al. (2009) produced an exceptionally broad and thor-
ough review of techniques for in situ imaging of metals in cells
and tissues.
Synchrotron access is necessarily limited, and experiment lead-
time from proposal to beamtime is typically six to nine months.
The techniques provide opportunities to advance presently
intractable questions, and many of the analytical techniques
available are highly complementary, require minimal sample
preparation, and may be performed with little or no signiﬁ-
cant damage to the sample. For technical resources and news
of developments at individual synchrotrons, readers are referred
to the most recent articles cited in this review, and to the web-
site www.lightsources.org/. Here, we provide some perspective on
developments in the ﬁeld over the past twenty years, drawing on
examples to show how pioneering experiments in synchrotron
X-ray research have contributed to our understanding of the
role of iron neurobiology, and by extension its role in various
neurodegenerative diseases.
DETERMINING IRON DISTRIBUTION AND FORM IN TISSUES
AND CELLS
Iron is the most abundant of the transition metals in human
brain, but to gain a full understanding of how iron in cells
and tissues is compartmentalized and bound requires exceptional
analytical sensitivity and speciﬁcity. While chemical and immuno-
histochemical methods have been successfully used to progress
understanding of iron and other metal elements at regional, cel-
lular, and sub-cellular level, they have limitations which have
prompted investigators to develop alternative techniques with
greater sensitivity, speciﬁcity, and spatial resolution for the analysis
of metal ions in tissues. The majority of systems are laboratory-
based, including particle-induced X-ray emission (PIXE), electron
probe X-ray microanalysis (EPMA), and LA-ICP-MS, reviewed in
depth elsewhere (McRae et al., 2009). Within the bio-iron com-
munity, arguably the best-known synchrotron X-ray technique
for iron analysis in tissues is SXRF, which has been demon-
strated at increasingly high spatial resolution and rapid analytical
rates to map cells and tissues in recent years (Collingwood et al.,
2005a; Tomik et al., 2006; Ortega et al., 2007; Popescu et al., 2009a;
Leskovjan et al., 2011; Ugarte et al., 2012).
SXRF MAPPING OF IRON IN TISSUES AND CELLS
When an X-ray beam interacts with a sample, it excites natu-
ral ﬂuorescence from the chemical elements within the tissue for
which the ﬂuorescence excitation energy is at or below the inci-
dent beam energy. The ﬂuorescent X-rays have element-speciﬁc
wavelengths, and their intensity determines the relative abun-
dance of each element. XRF was initially used with laboratory
systems to capture spectra from homogenized samples, but the
beam intensity and ﬁne optics control delivered by synchrotron
facilities has enabled SXRF to evolve into a technique for high-
resolution mapping of samples. The peak intensity for speciﬁc
elements, or the full ﬂuorescence spectrum, may be obtained in
each map pixel (Figure 1). SXRF emission is directly propor-
tional to atomic abundance, so in principle SXRF can be used
for quantitative analysis. SXRF mapping in biological samples
has mainly been semi-quantitative to date, where challenges with
matrix-matching, and localized foci of speciﬁc elements causing
heterogeneous patterns of self-absorption, hasmade true quantiﬁ-
cation impractical. The penetration depth of the beam is typically
≤1 mm, so that for the majority of cell or tissue samples the
beam will penetrate the full thickness and beyond; an exception to
this being the use of thick samples in rapid SXRF (Popescu et al.,
2009a). In the focused beam conﬁguration it has become standard
to map with resolution better than 100 nm at some beamlines; for
XANES it continues to be typical to work at micron-scale spatial
resolution.
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FIGURE 1 | Schematic illustrating a typical configuration for synchrotron
X-ray fluorescence analysis. For ﬂuorescence mapping (synchrotron XRF,
SXRF) the incoming beam is ﬁxed in energy, and the sample is moved
incrementally through the plane described by x and y. In panel (A), the full
ﬂuorescence spectrum is obtained at each point, and used to generate
element speciﬁc maps. Panel (B) shows the iron map for the region of
pigmented substantia nigra shown, corresponding to the region viewed via
the microscope camera (C). To obtain the X-ray absorption spectrum from a
point of interest in the sample, shown in panel (D), the beam energy is varied
and the XANES spectrum recorded.
X-RAY ABSORPTION SPECTROSCOPY ANALYSIS WITH XANES AND
EXAFS
Determining the oxidation state and structural environment of
iron in biological materials is a signiﬁcant analytical challenge;
more so if sample microstructure is to be preserved. Synchrotron
XAS is an attractive candidate to address questions about the
chemical state and mineralized form of iron in cells and tissues,
because of the exceptional sensitivity and spatially resolved pre-
cision with which microfocus XAS can be performed. XANES
provides chemical state information, and can be used to identify
the primary forms of iron oxide and/or iron-binding metal-
loproteins in the sample volume from which the spectrum is
obtained (Figure 1). For high-quality spectra (from, for example,
puriﬁed samples of iron-binding proteins), the energy spectrum
may be collected over an extended range, to obtain extended
X-ray absorption ﬁne structure (EXAFS), and the data utilized
to extract fundamental structural information about the local
environment. EXAFS can reveal the identities and structural
positions of atoms surrounding the scattering iron atoms: for
example, the neighboring shells of oxygen and iron atoms to deter-
mine the types of iron oxide found in ferritin, hemosiderin, and
neuromelanin.
The regions of the ﬂuorescence energy spectrum used in SXRF
mapping, XANES, and EXAFS are illustrated graphically in a
review of the analysis of metalloproteins in cells (Cook et al.,
2008), and below we consider the application of SXRF imag-
ing and XANES to analyze iron in various neurodegenerative
disorders.
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X-RAY FLUORESCENCE ANALYSIS OF IRON IN
NEURODEGENERATIVE DISORDERS
X-ray ﬂuorescence was used to analyze iron in neurodegenerative
disorders as early as 1968, using a laboratory X-ray source (Earle,
1968). XRF spectra showing elemental intensity as a function of
angle, determined by ﬂuorescence emission energy, were obtained
from the brain tissues of 11 PD cases and an unknown num-
ber of controls with no known neurological conditions. Emission
peak intensities were compared to obtain preliminary indications
about the concentration of iron and other elements in regions
of the brain. Detection limits were judged to range, for light to
heavy elements, respectively, from approximately 100 to 10 μg
element/g dried tissue. This enabled speciﬁc and simultaneous
analysis of physiologically important elements including the tran-
sition metals iron, zinc, and copper. Dissection and pelleting
of samples prior to analysis meant that information about iron
distribution in the tissue microstructure was not preserved. How-
ever, the heterogeneous and reproducible patterns of brain iron
deposition enabled comparisons of regional iron levels for health
and disease. Earle concluded that iron was consistently elevated
in PD brain tissue compared for control. As Earle found ele-
vated brain iron in a case of Pick’s disease, as well as in an
elderly man with a recent infarct, the brain iron changes were
not attributed as being speciﬁc to PD. Earle acknowledged the
limitations of using archived formalin-ﬁxed tissues (see Section
“Approaches to Study Design and Sample Preparation”), some of
which may have been in storage since 1862, and proposed that
the experiments be veriﬁed with unﬁxed tissue. This was done by
others in due course, including Dexter et al. (1989) and Jenner
(1989).
SXRF: THE EMERGENCE OF SYNCHROTRON X-RAY FLUORESCENCE
MAPPING
Synchrotron XRF provides orders-of-magnitude higher ﬂux than
can be achieved with bench-top X-ray systems. This, combined
with developments in optics to focus high intensity X-rays into
micrometer or nanometer diameter beams, signiﬁcantly improved
the signal that could be obtained from small sample volumes. It
became practical to obtain SXRF spectra from multiple points in
a sample, and to automate this process to obtain maps of cells
and tissues, with each pixel containing a complete metal-ion spec-
trum (Figure 1). Synchrotron beamlines utilizing soft X-rays now
routinely achieve sub-micron, and in some cases ∼10 nm spatial
resolution. This energy range is better-suited to light elements, and
for combined iron-ﬂuorescence and absorption analyses it is usu-
ally more efﬁcient to work at beamlines with access to the K-edge
for iron.
Ektessabi et al. (1999) collected SXRF spectra from dopamin-
ergic neurons in single cases of healthy control and PD brain, to
investigate elemental constituents, concentrations, distributions,
and chemical states of iron and other elements in the individ-
ual neurons. Mapping resolution was 6 μm × 8 μm, and incident
beam energy 13.5 keV.Areas∼ 100 μm× 100 μm were mapped in
formalin-ﬁxed tissue sectioned at 8 μm thickness prior to mount-
ing on Mylar ﬁlm. Consistent with prior XRF observations in
pelleted samples (Earle, 1968), they observed iron signal associ-
ated with the neuromelanin granules to be approximately twice
as intense in PD tissue compared to the control. Neuromelanin-
associated iron co-localized with other metals including calcium,
zinc, and copper. Efforts were made to determine the iron oxi-
dation state, but limited ﬂux in the microfocus conﬁguration
prevented useful XANES being obtained from such dilute sam-
ples (Ektessabi et al., 1999). Comparisons of iron signal within
and without the neuromelanin-rich neurons led to a reported
ratio of 11:1; this result in formalin-ﬁxed tissue is very different to
results from a subsequent independent study where we observed
a ratio ∼ 3:2 for neuron versus neuropil analysis in unﬁxed spec-
imens measured by EPMA, which then became ∼1:1 when iron
counts were normalized to sulfur counts (Oakley et al., 2007). One
interpretation of this difference is that extra-cellular (or weakly
bound) iron may have been selectively leached from the formalin-
ﬁxed tissue; however, the evidence in Ektessabi’s paper for raised
intra-neuronal iron in PD compared to healthy control is in good
agreement with our work in the unﬁxed tissues which conﬁrmed
raised iron for PD versus control (signiﬁcant at p < 0.0001) in
individual dopaminergic neurons using chemically unﬁxed speci-
mens from 16 PD cases and 14 controls without neurologic disease
(Oakley et al., 2007).
Subsequent to Ektessabi’s study, Szczerbowska-Boruchowska
et al. (2004) performed some of the earliest SXRF analysis on
unﬁxed tissues from neurodegenerative disorders, comparing iron
distributions in SN and spinal cord tissue from single cases
of PD and ALS and a control with no neurological disorder.
They worked with fresh-frozen 20 μm cryosections that were
freeze-dried following mounting onto a plastic (AP-1) foil. Adja-
cent tissue sections were used for supporting histology. Areas
500 μm × 500 μm were mapped at 10 μm × 5 μm resolution,
with higher resolution mapping (5 μm × 2 μm) of pigmented
neuronal cell bodies in the SN. With a dwell time of 3 s per point,
detailed maps could be obtained in a matter of hours. Relative
concentrations may be well-determined by SXRF, where sample
preparation and measurement conditions (such as detector posi-
tion) are identical, and data are normalized to incoming beam. In
the present study, standards were used to obtain apparent elemen-
tal concentrations, and detection limits were determined using
the following expression developed in keeping with the original





where the detection limit DLi depends on the mass per unit area
Ci for element i, the net peak area of element Yi for element i, and
the background Bi.
Szczerbowska-Boruchowska et al. (2004) observed that iron,
along with Zn, S, and Cl, was concentrated in the SN neuronal cell
bodies regardless of disease state. They observed, consistent with
the prior study in ﬁxed tissue (Ektessabi et al., 1999), elevation of
Fe (and other elements) in the PD SN compared to the healthy
control, seeing iron elevation in both nigral neuronal cell bodies
(perikarya) and white matter. It was noted that iron was “strongly
accumulated inside neuron perikaryal parts and, additionally in the
case of PD, in structures that were not identiﬁed histopathologi-
cally” (Szczerbowska-Boruchowska et al., 2004). The latter may
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have included extracelluar deposits (perhaps of neuromelanin) or
iron-rich glia. Neurons in the spinal cord, as compared to the SN,
did not carry the same typical elevation of Fe, but – in addition
to other elements including Ca and Zn – the apparent Fe con-
centration increased in ALS spinal cord white matter compared to
control.
While this study only included single cases, it is reportedly the
ﬁrst micron-level-precision spatial analysis of Fe focii in SN neu-
rons to be performed in chemically unﬁxed tissue; an important
step after the conﬁrmation by ICP-MS (in chemically unﬁxed bulk
tissue samples) of elevated iron in PD SN compared to healthy
controls (Dexter et al., 1989). Subsequent examination of spinal
cord using a slightly expanded number of ALS (n = 3) and control
(n = 5) cases found variable levels of Fe in the spinal cord neu-
ron perikarya and in the white matter. No signiﬁcant differences
were observed at whole tissue level (Tomik et al., 2006). The het-
erogenity of metal ion distribution in many atomical structures,
and the associated length scales, means that SXRF mapping is not
always an ideal tool for whole tissue comparisons unless anatom-
ical regions are very well matched: this is equally a challenge for
large-area rapid SXRF (Popescu et al., 2009a) as it is formicrofocus
studies. Here, prior observations had been made of elevated iron
and selenium in lumbar spinal cord from 38MNDcases compared
with 22 controls using bulk samples for neutron activation anal-
ysis (NAA). The marked elevation of Fe and Se, coupled with the
absence of correlation with disease stage or motor neuron counts,
prompted the conclusion that the Fe and Se elevation is an early
stage event in the disease process and likely a contributing factor
(Ince et al., 1994; Markesbery et al., 1995).
A strength of SXRF mapping is its ability to sensitively detem-
ine relative spatial distributions of elements at a wide range of
resolutions ranging from small anatomical regions and cell lay-
ers to the sub-cellular. Ortega et al. (2007) showcased sub-micron
SXRF by achieving 90 nm resolution mapping with an extended
version of the Kirkpatrick-Baez (KB) focussing geometry utilizing
the hard X-ray energy range, as shown in Figure 2. This study of
PC12 rat cells was designed to extend studies of iron in the SN
by looking at the relationship between iron and dopamine. The
PC12 pheocromocytoma cell line served as an in vitro model of
dopaminergic neurons; cells were differentiatedwith nerve growth
factor prior to exposure to sub-cytotoxic concentrations of iron
and/or AMT (alpha-Methyltyrosine), an inhibitor of dopamine
synthesis. The cells were freeze-dried prior to measurement, and
SXRF sampling times were 1/3–1 s per point with repeat sampling,
rather than extended dwell times, to achieve good signal:noise.
This is consistent with recommendations for optimal preserva-
tion of metal ion information in microfocus SXRF analysis of
biological materials (Bacquart et al., 2007). By utilizing a com-
bination of epi-ﬂuorescence to visualize dopamine, and SXRF
mapping for iron, they observed the co-localization of iron and
dopamine in dopamine vesicles, and demonstrated the impact
of dopamine synthesis inhibition on iron distribution. Use of
sub-micron resolution SXRF allowed detailed visualization of
neuronal processes in addition to the perikarya, revealing that
blocking dopamine synthesis led to lowering of iron content
speciﬁcally in dopamine vesicles, predominantly in the neuronal
processes.
FIGURE 2 | SXRF mapping with hard X-rays at sub-cellular resolution.
Dopamine-producing cells are chemically mapped with sub-90 nm beam,
revealing potassium and iron distribution. In panel (A) the intensity
distribution in the focal plane is shown; panel (B) illustrates the dopamine
producing cells exposed in vitro to 300 mM FeSO4 for 24 h. Chemical
element distributions of potassium (K) and iron (Fe) were recorded on
distinct cellular areas including cell bodies (C) and distal ends (D). Iron was
found in 200 nm structures in the cytosol, neurite outgrowths, and distal
ends, but not in the nucleus. Units for the min-max intensity bar are
arbitrary. Scale bars = 1 mm. Adapted from Ortega et al. (2007).
THE ADVENT OF QUANTITATIVE SXRF
The above study illustrated a signiﬁcant advance in synchrotron
hard X-ray capabilities, with a factor of 10 improvement in SXRF
imaging resolution, and a reported detection limit of 10−18 g
of Fe within a 100 nm diameter structure (Ortega et al., 2007).
Although SXRF is unique amongst the microprobes for its com-
bined sensitivity and non-destructive potential, it has historically
been recognized as a semi-quantitative method that demonstrates
consistent but relative (not absolute) metal ion distribution when
compared with quantitative microprobe techniques (Ugarte et al.,
2012; O’Reilly et al., 2014). The practical challenges of SXRF
analysis, including methods to analyse images and draw mean-
ingful comparisons between samples, are explored carefully in
a elemental analysis of breast tissue (Geraki et al., 2002); the
study also considers challenges in SXRF calibration. In princi-
ple, quantitative analysis requires matrix-matched standards that
have comparable bulk composition, density, and thickness of
the sample. Due to recent efforts, SXRF mapping is now being
recognized for its quantitative potential in the analysis of bio-
logical materials (Qin et al., 2011). Approximate concentrations,
sufﬁcient to permit a degree of sample comparison, have previ-
ously been obtained by use of standards or supporting analysis
of the sample materials. In Ortega’s analysis of the PC12 cells,
hundreds of additional cells were analyzed by microPIXE, to per-
form an approximate calibration for the SXRF nanoimaging via
mass normalization of the X-ray emission (Ortega et al., 2007).
Although the concentrations achieved are not absolute, this is a
good example of how complementary analytical approaches may
be used to overcome the limitations of a given technique. The
PC12 cell model was subsequently analyzed using the same SXRF
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and microPIXE approach to investigate competition between iron
and manganese (Carmona et al., 2010). Manganese toxicity can
result in a parkinsonism-like disorder in humans and it has been
postulated that Fe and Mn compete for serum iron binding pro-
tein transferrin, and subsequent iron transport protein divalent
metal transporter (DMT), but there is conﬂicting evidence as to
whether iron uptake is promoted or diminished by Mn exposure
in PC12 cells (Carmona et al., 2010). In addition to demonstrating
how Mn localizes to the Golgi apparatus, a decrease in intracellu-
lar Fe was observed after the cells were exposed to Mn, consistent
with the possibility that Mn competes with Fe for binding sites
and transport mechanisms (Carmona et al., 2010). An alterna-
tive approach to calibrate SXRF for elemental mapping in cells
incorporates the morphological data that can be obtained from
atomic force microscopy (AFM) and STXM, to correct for the
self-absorption effects that can strongly distort analysis of the
lighter elements such asmagnesium (Malucelli et al., 2013). Mean-
while, Kosior et al. (2012) have proposed what is reportedly the
ﬁrst method to achieve absolute quantitative analysis of iron and
other metal elements by SXRF, using quantitative phase contrast
imaging to obtain the projected mass for each sample, and thereby
perform the mass correction pixel-by-pixel for the SXRF maps.
This is designed to address the challenges for quantiﬁcation posed
by factors such as the variations at the cellular level in density
and cell thickness. Most SXRF analysis presently provides rela-
tive, rather than absolute, concentration maps of elements, as the
additional information required to convert SXRF maps to per-
form the mass correction (Kosior et al., 2012) is not yet routinely
acquired.
SXRF MAPPING: DEVELOPMENTS IN THE CONTEXT OF ALZHEIMER’S
DISEASE
In synchrotron studies to evaluate iron in neurodegenerative
disorders, the primary target regions have been those previ-
ously demonstrated to accumulate iron, to be especially prone to
degeneration, and/or to exhibit iron associated with pathological
hallmarks of a given disease. Some of the earliest SXRF map-
ping experiments were therefore of the cortex and hippocampus,
which undergo signiﬁcant atrophy in AD. For example Ishihara
et al. (2002) used small (3 mm × 4 mm) blocks of frozen tissue
from the superior temporal gyrus of two conﬁrmed AD cases,
brieﬂy ﬁxed in 4% paraformaldehyde and 2% glutaraldehyde for
2 h prior to cryosectioning at 5 μm thickness and mounting on
polyester (Mylar®) ﬁlm. Retrospectively, hematoxylin, and eosin
staining was used to determine tissue structure (Ishihara et al.,
2002). The small areas and absolute numbers of cells sampled,
in combination with the absence of a control for the AD cases,
limit the conclusions that can be drawn from this study. The ﬁx-
ation step also raises the possibility that loosely bound metal ions
may have been mobilized and displaced. However, this cellular-
resolution multi-elemental mapping of neuronal perikarya in the
cortex is an early demonstration of how SXRF was introduced to
study transition metal ion distributions in brain regions exhibit-
ing signiﬁcant pathology. SXRF was used during this same period
to compare elements including iron, zinc, and copper in frozen
unﬁxed rat brain tissue, as part of a study on iodine deﬁciency
(Zhang et al., 2002). Relative concentrations for hippocampus
versus cerebral cortex were plotted, but the structures within cor-
tex and hippocampus were not spatially resolved. As observed
for iron using histochemical methods (Morris et al., 1994), and
more recently for a range of metals using microbeam analysis, the
layers within the hippocampus exhibit distinct patterns of iron
and zinc distribution. The zinc elevation in the dentate gyrus has
been illustrated by SXRF in rat hippocampus (Flinn et al., 2005),
and the iron-rich layers in the layers of the surrounding cornu
Ammonis have been shown by SXRF in human hippocampus
(Antharam et al., 2012). It is of interest to determine these spatial
distributions of transition metals in the hippocampus, which is
especially prone to atrophy in AD, as analytical studies of bulk tis-
sue iron content in unﬁxed human hippocampus have produced
conﬂicting results as to whether iron concentration in the AD
hippocampus is elevated compared with healthy controls (Schrag
et al., 2011).
RAPID SCANNING SXRF
As the spatial resolution limits for hard X-ray SXRF of single cells
have been pushed in recent years (Ortega et al., 2007), so have the
rates at which large sample areas can be imaged (Popescu et al.,
2009a,c). The time required to map a sample is primarily depen-
dent on matrix size and the dwell time (or effective dwell time,
for raster scanning) per point in the matrix. It would usually be
desirable to map at a minimal resolution ∼50 μm, preferably
higher, to permit delineation of primary cell layers if not indi-
vidual cells. For a tissue section cut with thickness ∼20 μm, and
with typical elemental concentrations requiring ∼1 s per point
(including overhead) to obtain useful ﬂuorescence signal, it would
therefore take a little over 10 h to map a 10 mm × 10 mm area.
Use of synchrotron experiment time (beamtime) is often opti-
mized by minimizing the area required for scanning, and working
at the lowest resolution that permits the experiment aims to be
achieved. However, Nichol and colleagues have looked to over-
come the limited sample area that can be analyzed by SXRF by
developing an approach using very thick (conventional autopsy)
samples. This maximizes the opportunity for the incoming beam
to interact with the sample and thereby maximizes ﬂuorescence
yield from each anatomical region of interest, subject to any self-
absorption effects. As Popescu et al. (2009a) observe, the escape
depth is element-dependent, so although under most conditions
they can obtain relative metal ion distribution maps across a
sample area, the penetration depth for each map will differ as
a function of the element mapped. Their approach, utilizing thick
tissue slices and rapid SXRF scanning, has enabled transitionmetal
maps to be generated for selected regions of the central nervous
system in cases of PD, spinocerebellar ataxia, and healthy control
(Popescu et al., 2009a,b,c). This is an advance on histochemical
staining in that the elemental maps are achieved simultaneously
from a given sample, and there is excellent speciﬁcity (if spec-
tra are ﬁtted, rather than simply gated), for elements in addition
to iron such as copper and zinc, so long as the element-speciﬁc
differences in sampling depth are not critical to the experiment
design. Of the transition metals in brain tissue, Fe is the most
abundant on average, followed by Zn, and then Cu. One of the
sacriﬁces of rapid SXRF (which also arises in more conventional
microfocus SXRF measurements) is that in order to minimize scan
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time, the signal:noise for the individual pixel spectra are usually
insufﬁcient to gather robust data about other more dilute metal
ions present in the tissue such as Mn, as typically occurs when
working with an effective time of <6 ms per 40 μm pixel. This
can be addressed by reducing the scan rate to increase the effec-
tive dwell time per pixel (although this must be limited above
a certain value to avoid beam damage), or by repeating scans
(Bacquart et al., 2007). Althoughhigh effective in-plane resolution
can be achieved with rapid SXRF, the beam penetrates compara-
tively deeply into the sample at each point in the matrix, so that a
single pixel represents a small surface area but a signiﬁcant depth
[1/e attenuation of the Fe signal is quoted as 310 μm for brain
tissue (Hopp et al., 2010)]. The angle between the incoming beam
path and the ﬂuorescence detector is 90◦, and each is, respec-
tively, at 45◦ to the sample (see general illustration in Figure 1).
This path must be considered if trying to deﬁne boundaries in
order to undertake any high resolution multi-model analysis of
SXRF maps from thick samples. Each SXRF approach presents
constraints for sample preparation; for the rapid SXRF which
uses large-area thick sections, samples have been ﬁxed through
immersion in formalin, which others have reported provides a
vector for redistribution or loss of loosely bound metal ions (e.g.,
Szczerbowska-Boruchowska et al., 2004; Schrag et al., 2011). Vari-
ations in effective sampling depth occur as a function of element,
but also if there are signiﬁcant variations in the matrix (for exam-
ple, due to calciﬁcations, intense foci of the element beingmapped,
or variable hydration states). Fixed tissues have been protected
from dehydration by spraying the 1 mm-thick slices with buffered
formalin and heat-sealing under thin Mylar® prior to mapping
(Hopp et al., 2010).
The challenge of sample matching, in order to make compar-
isons between cases, is present for both rapid and microfocus
SXRF studies, albeit at different length scales. Where practical,
advance sectioning to ensure equivalent anatomical levels can sig-
niﬁcantly improve the comparisons that can be made. A rapid
SXRF study comparing a case of PD (male, 70 years old) and
healthy control brain (female, 80 years old) reveals many shared
structures, although the levels in the coronal sections are slightly
offset as described in the study and evidenced in hippocam-
pus proﬁles (Popescu et al., 2009a). The PD midbrain exhibits
a higher concentration of iron in the SN than for the control
(Popescu et al., 2009a), consistent with prior observations. The
midbrain section is taken at the level of the inferior colliculi so
the iron-rich red nucleus is not observed. The extent to which
offsets in level permit or preclude comparison will depend both
on the degree of heterogeneity of iron deposition in a given brain
region, and on the magnitude of differences between the study
groups.
VALIDATING MRI MEASUREMENT OF BRAIN IRON
As interest grows in the capacity of MRI to clinically analyse brain
iron (Drayer et al., 1986; Schenck and Zimmerman, 2004), there
is increasing need for direct validation of the indirect evidence
for iron contrast in MRI magnitude and phase data. Correlation
of MRI transverse relaxation with tissue iron concentration from
bulk tissue samples has previously been achieved for AD and con-
trol brains (House et al., 2008), but a number of factors, including
myelin, compete with iron to inﬂuence fundamental MRI param-
eters. As there is signiﬁcant heterogeneity in the microstructural
distribution andbound states of iron [as observed in hippocampus
(Antharam et al., 2012) and SN (Blazejewska et al., 2013)], there
is value in being able to directly describe the spatial relationship
between iron andMRI.Given the limited sensitivity of routine iron
histochemistry for this purpose [recently noted in postmortem
analysis of iron and MRI in the SN (Blazejewska et al., 2013)],
there have been growing efforts to correlate SXRF microscopy
mapswith the correspondingMRI data frompost-mortemhuman
tissue (Collingwood et al., 2008a; Hopp et al., 2010; Antharam
et al., 2012). This has included studies in formalin-ﬁxed tissue to
achieve approximate correlations between susceptibility-weighted
imaging (SWI) and iron maps for multiple anatomical regions
in each case via the rapid SXRF approach (Hopp et al., 2010),
and for the ﬁrst time in unﬁxed tissues, working at high spatial
resolution in thin sections to match SXRF iron maps with R2
and R2∗ maps, permitting detailed analysis of the hippocampus
in AD cases and age-matched controls and demonstration of a
positive correlation between iron and R2, R2∗ (Antharam et al.,
2012).
INVESTIGATING EVIDENCE OF OXIDATIVE STRESS IN
NEURODEGENERATIVE DISEASE WITH SXRF
The role of iron in neurodegenerative disorders is often consid-
ered in the framework of oxidative stress (Kell, 2010; Smith et al.,
2010). Analysis of selenium is important in this context, as it is an
essential element found in the cofactor for glutathione peroxidase,
which is involved in regulating oxygen free radicals. Selenium is
likely very important in protecting against free radical damage
from poorly liganded iron in neurodegenerative disorders. SXRF
is especially useful for sensitive and speciﬁc analysis of selenium
in tissue (Schulmann-Choron et al., 2000), where Schulmann-
Choron and colleagues obtained SXRF spectra from acid-digested
rat brain tissue, and reported a minimum detection limit (MDL)
of 20 ppb for selenium, using the full beam (focused to approxi-
mately 1 mm2), and counting for 500 s per acquisition. Ince et al.
(1994) had reported elevated iron and selenium in lumbar spinal
cord from MND cases compared with controls using NAA, and
in spatial SXRF analysis of SN and spinal cord in PD and ALS
cases, selenium was selectively observed in the neuronal bodies of
the SN (Szczerbowska-Boruchowska et al., 2004). Subsequently,
the SXRF investigation of neuromelanin in normal SN led to the
observation that selenium concentration in neuromelanin appears
to increase with age, and may indicate increased requirements for
protection against oxidative stress as a function of aging (Bohic
et al., 2008).
XAS: LOOKING AT THE OXIDATION STATE OF IRON AND ITS
LOCAL ENVIRONMENT
Determining absolute concentrations of tissue iron, and the pro-
portion of iron to which MRI sequences are sensitive, is important
to help with recognizing disruptions to iron homeostasis and
to identify potential clinical markers of disease. However, the
questions can become more subtle when we consider underlying
mechanisms of iron-mediated toxicity. Some instances of tissue
iron overload may be a consequence of impaired bioavailability
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(Rouault, 2013; Visanji et al., 2013), and under certain circum-
stances the colocalization of iron and species with, for example,
reductase potential like Aβ42 (Khan et al., 2006) or α-synuclein
(Davies et al., 2011), may be a more signiﬁcant contributing fac-
tor to oxidative stress damage than tissue iron concentration in its
own right (Gallagher et al., 2012; Everett et al., 2014a). As SXRF
may be used non-destructively, there is plenty of scope to correlate
SXRF iron maps with other parameters relevant to iron-mediated
toxicity, and to probe the oxidation state and mineral form of iron
within SXRF maps by techniques such as XANES (Collingwood
et al., 2005a; Bacquart et al., 2007).
Two decades ago, De Stasio et al. (1995) used X-ray secondary-
emission microscopy (XSEM) to spatially evaluate the chemical
distribution of iron and other metals in isolated rat cerebellar
granule cells after they had been exposed to iron in solution. The
iron absorption spectrum was measured between 50 and 60 eV,
and a difference image at the iron absorption edge between the
55 and 54 eV energies was calculated to gain a map of iron
distribution. The spatial distribution of the elemental analysis
was 0.5 μm or better. This particular experiment, perhaps due
to some limitation in the protocol, did not enable the associ-
ation of iron with particular cells or cellular structures to be
identiﬁed; rather, iron was found throughout the specimens.
However, in principle the absorption proﬁle can contain a great
deal of information about the local chemical environment of the
absorbing species, and below we consider how XAS, speciﬁcally
EXAFS and XANES, have been applied to the study of iron in the
brain.
Ascone and Strange have reviewed in detail the contribu-
tion of XAS to the analysis of metalloproteins (Ascone and
Strange, 2009), using the descriptor “metalloproteomics” deﬁned
as the “structural and functional characterization of metal-binding
proteins.” They acknowledge that XAS in biological materials
requires a synchrotron X-ray source to achieve the necessary
ﬂux, stability of the beam and associated optics, and the ultra-
sensitive ﬂuorescence detectors, along with a variety of highly
regulated sample environments. Concerning XANES of biolog-
ical materials, or “bio-XANES,” the importance of the pre-edge
spectrum, the developments in gaining quantiative structural
information from bio-XANES, and some limitations of “ﬁn-
gerprinting” with XANES are discussed. XANES and EXAFS
continue to be excellent tools for analysis of the electronic struc-
ture for metal elements in biological materials, and with an
expanding cross-disciplinary user base, there have been improve-
ments in both the sophistication and accessibility of purpose-
designed (and open source) software tools for analysis of the
spectra (Ascone and Strange, 2009). More complete studies
can be undertaken by combining synchrotron methods such as
EXAFS and X-ray diffraction for structural determination of
iron sites in multi-metal-bearing proteins (Einsle et al., 2007)
for metalloproteins such as ceruloplasmin (Ascone and Strange,
2009), or to evaluate trafﬁcking of metal ions between proteins.
Improvements in beamline instrumentation continue to improve
technical scope and measurement efﬁciency, and rapid acqu-
sition of high-quality XANES has enabled XANES “mapping”
at some beamlines with XANES obtained at each pixel in the
sample map.
X-RAY ABSORPTION SPECTROSCOPY TO STUDY IRON AND
NEUROMELANIN IN THE SUBSTANTIA NIGRA
Many experiments have now been performed to compare iron
in the SN in the healthy and PD brain. These experiments
have primarily been used to image or probe the distribution
of iron in tissue sections by various qualitative and quanti-
tative methods, or iron concentrations have been determined
for bulk samples. Spatial analysis of iron in unﬁxed tissues of
the SN has shown some evidence for site-speciﬁc elevation of
iron in PD dopaminergic neurons compared to healthy controls
(Szczerbowska-Boruchowska et al., 2004; Oakley et al., 2007), but
elevated iron concentration alone does not provide information
about the chemical form of the iron, or indicate whether excess
iron is bound in a state that differs from the iron normally present.
Here, we review XAS studies that have attempted to address this
question in the context of PD.
The dopaminergic neurons of the SN are selectively vulner-
able in PD and conﬁrmed to accumulate iron in the disease
state (Dexter et al., 1989; Oakley et al., 2007; Crichton et al., 2011).
These neurons are normally pigmentedwith neuromelanin, which
has a strong afﬁnity for metal ions including iron (Double et al.,
2003). X-ray microanalysis was performed on an electron micro-
scope to determine Fe2+ and Fe3+ associated with various forms
of neuromelanin, and from this it was deduced that the primary
form of iron in dopaminergic neurons is neuromelanin-bound
iron, and that neuromelanin preferentially binds Fe3+ (Jellinger
et al., 1992). X-ray analysis at various synchrotron facilities has
subsequently been used to further explore the nature of iron stor-
age inneuromelanin,which is considered important tounderstand
if we are to fully explain the contribution of iron-mediated toxicity
in PD.
Kropf et al. (1998) used EXAFS to look at the structure of
human neuromelanin and its analogs. They observed that both
human and synthetic neuromelanin have a common iron center
within a sixfold distorted oxygen octahedron, with a distance ∼
2 Å. Earlier studies with Mössbauer spectroscopy had reported
evidence for superparamagnetic behavior in both synthetic neu-
romelanin and puriﬁed human neuromelanin from the SN; in
the latter study, the parameters were observed to be similar to
those found for hemosiderin and ferritin (Gerlach et al., 1995).
Kropf et al. (1998) investigated the possibility that there are two
binding sites in neuromelanin, by looking with EXAFS at the near-
neighborhood environment of iron in both extracted human and
synthetic neuromelanin. The study included samples that were
either fully or partially (30%) saturated with iron, where for the
latter the most easily chelatable iron had been removed. As the
partially saturated human neuromelanin spectrum was virtually
indistinguishable from the saturated version, it was concluded
that there were no differences in the afﬁnities of the binding sites
(Figure 3). Melanin aggregation had formerly been described
using a fractal construct, implying a sponge-like structure, and
Kropf and colleagues reported their EXAFS observations as being
consistent with this model, suggesting that instead of two iron
binding sites, iron would simply be removed more rapidly from
outer than inner sites for a neuromelanin particle. The structural
information from the EXAFS indicated that a superparamagnetic
structure would be unlikely. Mössbauer spectroscopy was then
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FIGURE 3 | Continued
FIGURE 3 | Continued
X-ray absorption spectroscopy analysis of iron. Panel (A) shows EXAFS
spectra of iron bound to synthetic, natural 100% saturated, and natural 30%
saturated (depleted) neuromelanin, where the traces appear similar. Panel
(B) shows the processed EXAFS data reveal marked differences between
the synthetic and natural neuromelanin. Panels (C,D) show XMCD spectra
collected after 144 h for (C) ferrihydrite, and (D) ferrihydrite incubated with
Aβ42, where the positive and negative peaks (A,B,C,D) indicate an
antiferromagnetic structure, and the dramatically increased amplitude of
peaks (A,B) in panel (D) is consistent with a signiﬁcant increase in the
proportion of Fe2+ in the antiferromagnetically ordered mineral. Panels
(A,B) were published in Kropf et al. (1998), Copyright Elsevier (1998). Panels
(C,D) are adapted with permission from Everett et al. (2014a). Copyright
2014 American Chemical Society.
used to demonstrate that the neuromelanin exhibited only para-
magnetic behavior (Kropf et al., 1998), and it was concluded that
the iron in neuromelanin does not follow the ferritin model in this
regard.
In a parallel study, EXAFS was used to analyze iron in whole
tissue samples that had been gently homogenized prior to analy-
sis (Grifﬁths et al., 1999). The study included samples from the
SN and GP regions in a group of PD cases and healthy con-
trol brains, with n = 6 in each group. For the tissue, it was
concluded that ferritin-like parameters provided the most appro-
priate ﬁt for both anatomical regions. This result for SN is not
necessarily in contradiction of the former neuromelanin analysis
(Kropf et al., 1998), which was performed on isolated neurome-
lanin and would not have included iron from other sources such
as astrocytes, oligodendrocytes, and activated microglia in the
vicinity of extracellular neuromelanin. Indeed, it has been sug-
gested that neuromelanin-bound iron would not exceed ∼15%
iron in the SN (Galazka-Friedman et al., 1996). Given the hetero-
geneous nature of iron andneuromelanin distribution throughout
the subﬁelds and cell types in the SN (Morris and Edwardson,
1994), the exact region dissected for analysis will inﬂuence the
proportion of tissue iron that is neuromelanin-bound; it has
also been suggested that the strong afﬁnity of neuromelanin for
iron leads to additional iron from other sources (such as glia)
binding neuromelanin during the extraction and puriﬁcation pro-
cess, as neuromelanin is not normally saturated (Double et al.,
2003). Based on the number of parameters required to ﬁt clus-
ters of electron-dense cores in these same samples (observed by
electron microscopy), it was concluded that a greater degree of
sub-cellular clustering occurred within PD tissue than in controls
(Grifﬁths et al., 1999). While this was interpreted as a change in
sub-cellular clustering of ferritin, it is possible that for SN this
observation included neuromelanin clusters, consistent with for-
mer histopathological observations and a concurrent study from
Ektessabi et al. (1999) using SXRF imaging of PD and control SN
where they noted “various sizes of melanin granules released from
dying nigral neurons scattered in a more condensed form (neurome-
lanin aggregates) than those in the nigral neurons of the control
subject.”
Ektessabi et al. (1999) had originally been unable to obtain
useful XANES data from the formalin-ﬁxed SN tissues that they
mapped by SXRF, but at the 39XU Spring-8 Japanese synchrotron
they mapped a small area at 7.2 keV, just above the iron K-edge,
prior to obtaining XANES in the ﬂuorescence conﬁguration with
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a beam spot limited with a pinhole to approximately 10 μm in the
sample plane (Yoshida et al., 2001). Reference standards of FeO
and Fe2O3 were used in order to determine the position of the
Fe2+ and Fe3+ edges, respectively, and to thereby compare relative
proportions of Fe2+ and Fe3+ at sites of interest throughout the
SN. It is reported that with a 0.5 eV energy step, that dwell times
ranged from 20 to 100 s per step (Yoshida et al., 2001). While com-
parisons between neuromelanin-bound iron in intact and dead
neuronsweremade (which suggested an increased fraction of Fe3+
in neuromelanin associatedwith degenerating neurons), the use of
a single case, and the prior ﬁxation and parafﬁn embedding of the
tissue means that this study is more signiﬁcant as a demonstration
of potential for iron XANES from individual cells in sections of
human brain tissue.
MicroXANES in unﬁxed SN tissue was performed by Chwiej
et al. (2007), where a single PD case and six controls were com-
pared in freeze-dried tissue. Regions of pigmented neuromelanin,
consistent with those observed in dopaminergic neurons, were
selected for XANES analysis, and no signiﬁcant difference between
thePDand control sampleswas detected. In contrastwith the prior
XANES reported from ﬁxed tissue (Yoshida et al., 2001), the only
detectable chemical state of the iron in these unﬁxed tissues was
Fe3+ (Chwiej et al., 2007). This observation, while it contradicts
prior reports of Fe2+ in normal PD SN, is strongly supported by an
earlierMössbauer analysis of SN fromPD and control cases, where
only Fe3+ was detected in bulk tissue samples (Galazka-Friedman
et al., 1996).
The XANES study by Baquart el al, analysing PC12 cells as
a model system for the SN (Bacquart et al., 2007), is especially
thorough in assessing the impact of sample preparation and
beam exposure on the scope for radiation damage in the form
of mass loss (Williams et al., 1993) and photoreduction (Yano
et al., 2005). This XANES study was concurrent with members
from the same team reporting high resolution SXRF analysis of
iron and dopamine vesicles in the same cell model (Ortega et al.,
2007). XANES was selected for its scope for measurement with
minimal preparation of the cells, avoiding processes that might
modify the chemical species. Beam focus of 1.5 μm × 4 μm
was achieved with K–B mirrors, and iron and arsenic were ana-
lyzed by XANES captured in ﬂuorescence mode (which is optimal
for dilute specimens). Regions sampled within the PC12 cells
included cytosol, the mitochondrial network, and nucleus. It
was observed that cells measured in the frozen hydrated state
(maintained at –100◦C, in a liquid nitrogen cryostream) were
generally preferable to freeze-dried cells at room temperature, as
this increased repeatability, sensitivity, led to no noticable shift
in oxidation state, and minimized beam damage. Interestingly,
however, it was observed that for iron, any change in chemi-
cal state between the frozen hydrated and freeze dried cells was
insigniﬁcant in the XANES, and that the technically more straight-
forward method of working with the freeze dried cells at room
temperature, facilitating observation with the videomicroscope
during measurement, made this the preferred option (Bacquart
et al., 2007). To achieve good signal to noise, with minimal beam
damage to the sample, it was noted that short repeated energy
scans were preferable to a single scan with longer dwell times
at each energy. Iron XANES at the K-edge (7.112 keV) were
obtained over the energy range 7.037–7.200 keV, collecting for
5 s/step, with a step size of 1.0 eV pre- and post-edge, and 0.5 eV
through the edge region (7.082–7.142 keV), giving a scan time of
approximately 18 min. (Scan times longer than this led to sig-
niﬁcant signal decay for XANES of arsenic in the freeze dried
cells at room temperature, indicating mass loss of this element.
Mass loss was tracked by decreasing white line intensity; notably,
the dose observed to cause mass loss in the hard X-ray region
at room temperature did not have the same effect with soft X-
rays at 113 eV, or under cryoconditions, where both protected
against mass loss. Minimizing the dose was also important to
reduce scope for photoreduction by the X-rays.) The microfo-
cussed achromatic beam was very stable; beam movement on the
sample corresponded to a displacement of approximately 0.1 μm
over 100 eV. While the short XANES scans could be repeated and
summed to improve signal qualitywithout causingdetectable sam-
ple damage, the iron concentration in the PC12 cells was sufﬁcient
that good XANES data were acquired in a single acquisition. The
“limit of speciation” for elements in the atomic mass range of
20–40 was judged to be approximately 13 μg/g (Bacquart et al.,
2007). Progress in synchrotron technology is resulting in samples
being exposed to higher photon ﬂux, so the conditions required
for sample preservation will require ongoing evaluation (George
et al., 2012).
X-RAY ABSORPTION SPECTROSCOPY TO STUDY IRON IN FRIEDREICH’S
ATAXIA
In order to study mitochondrial iron chemistry in the context of
Friedreich’s Ataxia, Popescu et al. (2007) analyzed the heavy mito-
chondrial fraction isolated from primary ﬁbroblasts taken from
individuals with and without Friedreich’s Ataxia, and analyzed
them by XANES at the iron K-edge. In order to determine the
mineral state of the iron, they ﬁtted the spectra with a library of
22 iron compounds, and concluded from the ﬁtting results (with
supporting data from Western blotting) that the mineralized iron
in the Friedreich’s Ataxia patients is more highly organized than in
the unaffected individuals, and that the Friedreich’sAtaxia patients
mineralize a signiﬁcant fraction of cellular iron in mitochondrial
ferritin (MtFt; Popescu et al., 2007). MtFt has been postulated
as having a protective role for mitochondria in cells which have
high levels of metabolic activity and oxygen consumption, rather
than being associated with iron storage (Levi et al., 2001), and
since Popescu’s XANES analysis, this potentially protective role
has been explored speciﬁcally in the context of Friedreich’s Ataxia
(Campanella et al., 2009).
COMBINING SYNCHROTRON X-RAY FLUORESCENCE
MAPPING AND ABSORPTION SPECTROSCOPY
As the microfocus SXRF and XANES techniques mature, there
has been increased recognition of their complementarity, and
many microfocus beamlines are now well-equipped to measure
both during the course of an experiment (Figure 1). Practical
measures such as simultaneous acquisition of CCD data in trans-
mission mode to determine crystalline parameters of biominerals,
and introducing custom lithographic ﬁnder grids to aid location
and retrospective analysis of sites within a sample, have previously
been proposed (Collingwood et al., 2005b).
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INVESTIGATING IRON BIOMINERALIZATION IN ALZHEIMER’S DISEASE
One of the early applications of the combined SXRF and XANES
analysis was to demonstrate how isolated microscale iron focii
in large (≥1 cm2) areas of tissue could be efﬁciently identiﬁed
and characterized in a way that is impractical or impossible with
other microprobe techniques. The motivation for this work was
the detection of tiny deposits of magnetite, a mixed valence iron
oxide, in human brain tissue, via analysis of bulk tissue samples
and isolated material (Kirschvink et al., 1992; Dunn et al., 1995).
There were early indications that levels of magnetite were elevated
in AD tissue compared for healthy controls (Hautot et al., 2003),
although the extent of this, and the mechanism for its forma-
tion in vivo, was relatively unexplored. Our preliminary work with
avian tissue (Mikhaylova et al., 2005), known to containparticulate
magnetite, established the protocols for the ﬁrst demonstration
of magnetite in situ in human brain, using AD amyloid-plaque-
rich tissue from the superior frontal gyrus (Collingwood et al.,
2005a). SXRF mapping at resolutions ranging from 100 to 5 μm
were used to detect and precisely locate iron focii, and XANES
analysis was performed with the 5 μm beam spot to determine
the forms of iron present at the sites, which primarily included
ferritin-like ferrihydrite, and/or magnetite. The combination of
SXRF and XANES has since been used to study the amyloid-
β precursor protein (AβPP)/presenilin 1 (PS1) mouse model of
AD (Gallagher et al., 2012). This model is engineered to over-
express the Swedish mutation of humanAβPP, and mutant human
PS1, and is known to exhibit amyloid deposition in the brain
from approximately 6 months. SXRF and XANES were used to
demonstrate magnetite deposits in amyloid-rich regions of the
AβPP/PS1 transgenic mouse brain (Gallagher et al., 2012), and in
this study we suggested that the magnetite deposits are an indi-
cation that iron dysregulation is an early event in AD-related
pathology. Subsequently, in work led by the Telling group, we
suggest a mechanism, demonstrated in vitro by synchrotron meth-
ods including XAS and X-ray magnetic dichroism (XMCD), by
which the reductase behavior of Aβ42 may lead to the obser-
vation of magnetite in these plaque-rich tissues (Everett et al.,
2014a).
UNDERSTANDING NEUROMELANIN
Another area in which the combination of SXRF and XANES has
been utilized, is in the study of neuromelanin in human tissues
(Bohic et al., 2008). SN tissue was obtained from formalin-ﬁxed
parafﬁn embedded samples from seven human brains ranging
in age from 24 weeks to late adulthood, and the cases were
selected on the basis of having no signiﬁcant neuropathology,
SN related pathology, or dopamine-related disorders. Pigmented
neurons were SXRF mapped, and then XANES obtained at the
K-edge in ﬂuorescence mode in 1 eV increments over the range
7.07–7.37 keV. The authors report increased levels of cellular
neuromelanin, followed by a darkening of the pigment, as a
function of aging. From the trace metal mapping it was estab-
lished at a high level of spatial resolution that iron and selenium
are closely associated with neuromelanin from an early stage of
development, and that other metals such as calcium, copper,
and zinc become associated with it at a later stage. The levels of
neuromelanin-bound iron in the tissue were below the expected
saturation value for neuromelanin, consistent with prior work
(Double et al., 2003). The intensity of the SXRF spectra indi-
cate that neuromelanin-bound iron increases as a function of age,
although the microXANES spectra were consistent with ferritin
regardless of age. It should be noted that the chemical form of
iron in the SN was shown by Mössbauer to be demonstrably dif-
ferent in formalin-ﬁxed archive samples compared for fresh-frozen
(Galazka-Friedman et al., 1996), but here the XANES conclu-
sions are generally consistent with those previously obtained in
unﬁxed sections (Chwiej et al., 2007). Bohic et al. (2008) con-
clude, contrary to prior EXAFS observations in extracted human
neuromelanin (Kropf et al., 1998), that neuromelanin is likely to
have variability in its metal binding domains that suggest differ-
ent functional roles. There is, however, unanimous agreement
between all four studies cited here that the iron bound to neu-
romelanin is in the Fe3+ form within the limits of experimental
error. A subsequent study of extracted neuromelanin granules was
conducted by Tribl et al. (2009), where a variety of proteins were
shown to be associated with neuromelanin, including L-ferritin.
This observation may in due course contribute to explaining
the multiple binding afﬁnities reported for neuromelanin, and
arguably there is an opportunity here to combine immunohis-
tochemistry with sub-micron SXRF and XANES to determine
if and how L-ferritin colocalises with neuromelanin in intact
pigmented cells.
IRON-BINDING PROTEINS AND AGGREGATION
Themain emphasis of the previous sections in this review has been
on the use of synchrotron techniques to locate and characterize
iron, including that which is tightly coordinated to metallopro-
teins. Synchrotron analysis also has the scope to provide insights
where metalloprotein structure and conformation is concerned,
which is an essential aspect of understanding iron regulation (and
by extension dysregulation) in neurodegenerative disorders.
Synchrotron techniques have been used for analysis of a
variety of iron-binding metalloproteins, including transferrin,
hemoglobin, and ferritin, where the latter has been investigated
in many synchrotron experiments to further understand both the
protein structure, and the nature of the iron oxide core formed
within (Kim et al., 2011). The powerful combination of high reso-
lution X-ray crystallography and EXAFS has been especially useful
in determining the structure of metalloproteins (Hasnain, 2004;
Duke and Johnson, 2010). One of the advantages of synchrotron
X-ray crystallography is the rapidity with which diffraction pat-
terns can be obtained from highly complex structures. Several
groups have used time-resolved Laue diffraction studies to inves-
tigate structure and conformational properties of metalloproteins
(Duke and Johnson, 2010). For example, Bourgeois et al. (2003)
reported the application of nanosecond Laue crystallography to
determine protein structure using myoglobin as model system.
This study with 150 ps X-ray pulses enabled room temperature
observation of the dynamics of protein conformational changes.
SMALL ANGLE X-RAY SCATTERING
Awidely used synchrotron technique for the conformational study
of metalloproteins is small angle X-ray scattering (SAXS), which
has been used to look at proteins intimately involved in the uptake
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and transport of iron. As with crystallography, time resolution
can be a useful feature in SAXS measurements, enabling tran-
sient aggregates to be distinguished from folding intermediates
(Segel et al., 1999). Castellano et al. (1993) used SAXS to look
at the conformational changes in aggregates of human transfer-
rin. They looked speciﬁcally at transferrin from human serum
(serotransferrin), an 80 kDa metal binding protein which is struc-
turally modiﬁed on binding to metal ions, and which has sites
for two Fe ions. This investigation was motivated by a desire to
understand the potential role of transferrin in binding Cu and
Al in addition to Fe. Castellano’s study included observations of
apotransferrin and monoferric transferrin, and they concluded
that the conformational changes brought about by the iron bind-
ing process were consistent with prior observations made with
both X-ray and neutron scattering methods. The transferrin
was considered in a fractal framework, permitting particle and
cluster sizes to be distinguished (Castellano et al., 1993). More
recently, it has been observed that transferrin can form ﬁbrils
under certain conditions in vitro, and this led to an investigation
to determinewhether transferrin has amyloid-like properties. Syn-
chrotron X-ray circular dichroism (XCD) was used to test whether
transferrin in solution has amyloid-like properties, and this helped
show that transferrin aggregation in solution does not appear to
involve major structural changes to the protein, or formation of
beta-pleated sheets (Booyjzsen et al., 2012).
Small angle X-ray scattering is ideal for studying protein
(mis)folding and aggregation problems, which are a common
feature in neurodegenerative disorders. In turn, iron and other
metal elements are associated with modifying or exacerbating
protein aggregation in the majority, if not all, of these disorders
(Kell, 2010). SAXS permits the size and shape of soluble aggre-
gates to be characterized, and can provide information about
the order of aggregation (i.e., whether it is a dimer, trimer, or
higher order). One protein that has been studied in detail by
SAXS is α-synuclein, which forms insoluble ﬁbrils in neurode-
generative disorders classed as the “synucleinopathies,” including
PD, dementia with Lewy bodies (DLB), and MSA. Uversky et al.
(2002, 2005) conducted a series of studies incorporating SAXS,
which investigated the conformation, shape, and association of the
α-synucleins in solution. Typical experiments were performed at
room temperature, and involved the α-synuclein passing through
a ﬂow cell along a 1.3 mm path, with 25 μm mica windows (Li
et al., 2001). SAXS permitted wild-type, and familial PD point
mutations (A30P and A53T) to be distinguished, determining
the radius of gyration, Rg, and the conﬁrmation and globular-
ity (indicating packing density) of the protein. It was observed
that the wild-type and mutated forms of α-synuclein have iden-
tical Rg of 40 Å at neutral pH, and that this value decreases as
the pH is lowered, indicating compacting of the protein giving
rise to a reduction in volume. The homogeneity of the pro-
teins, the absence of aggregation under these conditions, and the
conﬁguration approximating to a random coil at neutral pH is
also demonstrated through the SAXS data (Li et al., 2001). Sub-
sequent studies considered in more detail the monomeric and
ﬁbrillar forms of α-synuclein, including exploring factors that pro-
mote and inhibit aggregation (Uversky et al., 2002, 2005). Recent
advances in time-resolved XAS include work from Lima et al.
(2011) to enable MHz-rate data acquisition with picosecond lasers
to enable studies at physiologically relevant concentrations for
biological systems.
SYNCHROTRON FOURIER-TRANSFORM INFRA-RED ANALYSIS
To study proteins such as α-synuclein, Aβ, and prion protein in
intact tissues, another technique may be used: FTIR spectroscopy,
where the infrared spectrum is obtained from a given material.
FTIR is routinely performed using laboratory sources, but for cer-
tain measurement conﬁgurations, synchrotron light sources have
capacity to achieve brightness that is orders of magnitude brighter
than standard sources. A detailed review of the principles of the
instrumentation, and of approaches to biological specimen prepa-
ration for FTIR, is provided by Miller and Dumas (2006), who
consider FTIR micospectroscopy (FTIRM), and imaging (FTIRI).
Where the beam spot size at the sample is determined by a pinhole,
synchrotron FTIR is especially advantageous for microscale anal-
ysis with resolution ∼ 10 μm. The spatial resolution of FTIRM is
limited by the wavelength of the infrared, from approproximately
1.7 μm at 4000 cm−1 to 13 μm at 500 cm−1. Spectra from biolog-
ical samples are obtained in transmission mode with thin samples
(typically 5–30 μm), or in reﬂection mode for highly reﬂective or
unsectionable samples (Miller and Dumas, 2006).
Fourier transform infraredmay be used to study protein folding
dynamics on the microsecond time scale, at good spatial resolu-
tion and with a small volume of sample. While slower than laser
techniques, the white beam ensures the complete spectra can be
obtained (Miller and Dumas, 2006). However, one of the most
interesting applications of FTIR is the subcellular chemical map-
ping that can be achieved, which is highly complementary to the
analysis of metal andmineral structures outlined previously in this
review. FTIR gives insight into the nucleic acid, protein, and lipid
content of particular structures, and does not signiﬁcantly heat
the sample, so that prolonged studies of individual living cells may
be performed. Multimodal imaging, such as combining SXRF and
FTIRM with epiﬂuorescence microscopy to look at trace metals
and AD senile plaques (Miller et al., 2006), can be done with ﬂu-
orescent tag concentrations at levels that do not interfere with the
infrared, and there is growing interest in combining synchrotron
FTIR, SXRF, and XAS (Miller et al., 2006; Kastyak et al., 2010). For
example, Kastyak et al. (2010) used synchrotron FTIR to analyze
crystalline deposits of creatine detected in SXRF-mapped unﬁxed
tissue from spinal cord, brain stem, and motor neuron cortex in
cases of ALS. Intense focii (“hot spots”) of calcium, zinc, iron,
and copper were also noted in the ALS tissues. Miller et al. (2006)
initially demonstrated the combination of SXRF microfocus map-
ping and FTIR to unambiguously associate iron, copper, and zinc
with Aβ deposits in unﬁxed air-dried human brain tissue from
AD cases. FTIRM and SXRF were mapped with a resolution of
5–10 μm, and the Amide I absorbance was used to conﬁrm the
presence of Aβ. Tissue sections were mounted on quartz after
the slides had been coated with a 200 nm sputtered coating of
aluminum. The latter was necessary for infrared reﬂectivity, but
the spatially heterogeneous trace contamination of iron in even
this thin aluminum layer place some constraints on the tissue
iron analysis that could be performed in this study. The copper
and zinc distributions (as demonstrated by SXRF) showed good
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correlation with regions containing Aβ deposits (as demonstrated
by FTIR). In a subsequent study, using Ultralene® as an ultra-clean
SXRF and FTIR compatible substrate for the tissue samples, the
correlation between transition metal ions and amyloid deposition
was investigated for the AβPP/PS1 mouse model of AD (Leskov-
jan et al., 2011). Sections were cut at 30 μm thickness, air-dried,
and kept in a dessicator prior to imaging. Approximate quan-
tiﬁcation of elemental concentrations was achieved using thin
ﬁlm standard reference materials. Amyloid was visualized with
a simple Thioﬂavin-S staining protocol, where they observed no
change in the iron, copper, or zinc content of the map subse-
quent to staining, and FTIRM was used (in transmission mode)
to determine tissue protein density using a spatial mapping res-
olution of 4 μm. Normalization of metal ion content to protein
content for each selected plaque was used to determine whether
iron, copper, and zinc accumulate in large dense areas of amy-
loid deposition in the AβPP/PS1 model of AD; it should be noted
that only large plaques (30–50 μm) were included in the quan-
titative correlations, to ensure they occupied the full thickness
of the section. Analysis of regional iron, copper, and zinc distri-
bution was achieved by a combination of standard segmentation
(e.g., of the hippocampus) and by cluster analysis. Interestingly,
with SXRF microscopy, an elevation (∼1/3) of cortical iron was
observed in the AD model compared to the wild type, which is
consistent with observations from Smith et al. (2010) in human
AD and the iron was not directly associated with the large regions
of amyloid deposition that were included in the analysis. Zinc,
however, became associated with the amyloid deposits at the end-
stage of the study (56 weeks), having not demonstrated elevation
at 24 and 40 weeks. Leskovjan et al. (2011) acknowledge that there
may possibly be a relationship between brain iron and the amyloid
pathology, but given that iron was not speciﬁcally elevated at the
amyloid-plaque sites, when normalized to protein content, there
was clearly some doubt. Their study highlights an important ques-
tion about the manifestation of iron dysregulation in AD: does
tissue iron have to be signiﬁcantly elevated above normal con-
centrations in order for iron to contribute to pathophysiological
processes?
DISCUSSION
DOES IRON-MEDIATED TOXICITY DEPEND ON IRON CONCENTRATION?
Historically, attention has been paid to brain cells, tissues, and even
whole brain regions exhibiting marked changes in iron concentra-
tion. These indicate candidate sites vulnerable to iron-mediated
toxicity, but analyses that focus purely on iron concentration in tis-
sue have been challenged (Friedman et al., 2009), and lead in many
cases to conﬂicting observations (Friedman et al., 2009; Schrag
et al., 2011), and the contribution of iron overload to pathology
is unclear (Rouault, 2013). Kell considers the problem from the
perspective of poorly liganded iron (Kell, 2010), placing emphasis
on the local chemical environment, and the availability of iron to
participate in reactions that stimulate the overproduction of dam-
aging radical species. We suggest here that signiﬁcantly elevated
concentrations of iron are not a prerequisit for this scenario.
We will take Aβ aggregation as a case study, where the interac-
tions between Aβ42 and iron in vitro, and the relationship between
Aβ and iron deposition in humans and AβPP mouse models,
have been characterized by synchrotron methods (Collingwood
et al., 2005a; Gallagher et al., 2012; Everett et al., 2014b). Many
studies have demonstrated that iron is associated with insoluble
deposits of Aβ in human brain, even in the pre-clinical stage of
AD (Smith et al., 2010), and it is understood that iron provides
much of the natural contrast that makes amyloid plaques observ-
able in high resolution MRI (Meadowcroft et al., 2009; Petiet
et al., 2011). However, observed accumulation of iron in amy-
loid plaques is reportedly lower in mouse models of AD than in
human tissue (Leskovjan et al., 2009; Meadowcroft et al., 2009),
and tissue iron concentration has been shown not to correlate
with plaque burden in human AD cases (House et al., 2008).
This observation was reinforced in study of 60 aged human
brains, where it was demonstrated that there is no relation-
ship between tissue iron concentration and congophilic amyloid
angiopathy or senile plaque burden (Exley et al., 2012). The
formation of spherulites from Aβ42 has been demonstrated in
the presence of copper (House et al., 2009), and it is postu-
lated that these structures, which form in vitro and are also
observed in human brain tissue, may correspond to the senile
plaques with ﬁbrillar structure routinely observed with trans-
mission electron microscopy. SXRF microfocus analysis of the
spherulites in unﬁxed human AD hippocampus revealed direct
association of the spherulites with copper, not iron, despite
iron being abundant in the tissue (Exley et al., 2010). Sub-
sequent Perls staining in formalin-ﬁxed human hippocampus
from another individual also showed no direct positive corre-
lation between iron and spherulite distribution (House et al.,
2011). In our SXRF analysis of AD and control hippocampus,
where microfocus-resolution iron maps were correlated with MRI
microscopy, again no disease-dependent change in total regional
iron level was observed, although the AD tissue exhibited a
higher proportion of R2 and R2∗ hyperintensity artifacts consis-
tent with iron-rich deposits within the hippocampus (Antharam
et al., 2012). It is therefore necessary to consider not only concen-
tration of iron and its co-localization (or otherwise) with Aβ, but
also the chemical and bound state of iron in tissues exhibiting
amyloid aggregation. Synchrotron facilities provide exception-
ally sensitive and unambiguous techniques for this purpose. Our
study with SXRF and XANES to investigate the mineral form of
iron deposits in human AD plaque-rich cortical tissue demon-
strated the presence of ferrihydrite (Fe3+, consistent with normal
ferritin cores) and magnetite (alternating lattices of Fe2+ and
Fe3+) within the tissue (Collingwood et al., 2005a); an obser-
vation subsequently supported by the detailed characterization
of ferritin-core-sized magnetite/maghemite iron oxide particu-
lates in extracted amyloid plaque core materials (Collingwood
et al., 2008b). The subsequent SXRF and XANES analysis in the
AβPP/PS1 model produced essentially the same observation con-
cerning magnetite formation, despite quantitative analysis of the
same brains showing no overall difference in brain iron concen-
tration between wild-type and the AD mouse model (Gallagher
et al., 2012).
What is the origin of the mixed valence oxides observed in
the human and mouse model tissues, and is their association
with regions exhibiting Aβ deposition a coincidence? The reduc-
tase behavior of Aβ42 peptide, a primary component of amyloid
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pathology in AD, has been demonstrated in vitro, where it has
the capacity to reduce iron from its more stable ferric (Fe3+)
form to the more reactive bio-available ferrous (Fe2+) form at
physiological pH (Khan et al., 2006; Everett et al., 2014b). Using
a combination of XAS (using the total electron yield method),
and XMCD by obtaining two XAS spectra with opposed mag-
netic ﬁelds oriented in the direction of the X-ray beam (Figure 3),
we have now shown that Aβ42 has the capacity to chemically
reduce iron in ferrihydrite particles (Everett et al., 2014a), and
the results from this in vitro study support the possibility that the
Fe2+ oxide that forms in the presence of Aβ1−42 is a precursor
to magnetite formation (Everett et al., 2014a). These results are
further supported by chemical imaging using STXM (Figure 4).
Cellular ferrireductase behavior by α-synuclein, a peptide which
is a key constituent of protein aggregates in PD, DLB, and MSA,
has also been observed (Davies et al., 2011). These results indicate
that co-localization of trace levels of labile or poorly liganded
iron with aggregating Aβ1−42 or α-synuclein has the potential to
lead to signiﬁcant overproduction of radical species in various
neurodegenerative disorders.
Taken together, these synchrotron observations by FTIR and
SXRF (Leskovjan et al., 2011), SXRF and XANES (Collingwood
et al., 2005a; Antharam et al., 2012; Gallagher et al., 2012), and
XANES and XMCD (Everett et al., 2014a,b), support the sugges-
tion that mineralized iron deposits may prove a useful clinical
marker of amyloid-mediated iron deposition (Meadowcroft et al.,
2009; Petiet et al., 2011; Antharam et al., 2012), and they provide
strong support for the hypothesis that interaction mechanisms
FIGURE 4 | Illustration of STXM chemical mapping of iron associated
with aggregated Aβ4 2. Panel (A) shows bright-ﬁeld transmission electron
microscopy (TEM) images and panel (B) shows scanning transmission X-ray
microscopy (STXM) images of ﬁbrillar amyloid structures formed following the
incubation of Aβ42 with ferrihydrite. TEM pictures show Aβ structures present
after 0.5, 48, and 144 h of incubation. STXM images show the carbon (C) and
iron (Fe) content of an Aβ/ferrihydrite aggregate, along with a carbon/iron
(C + Fe) composite image of the same aggregate. Reprinted (adapted) with
permission from Everett et al. (2014a). Copyright 2014 American Chemical
Society.
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between iron and aggregatingAβ, rather than necessarilymeasures
of total iron concentration or co-localization of iron and amyloid,
are critical to our understanding of Aβ-mediated toxicity in AD.
APPROACHES TO STUDY DESIGN AND SAMPLE PREPARATION
As technical developments at synchrotron facilities have enabled
and encouraged a growth in metallomics research over the
past twenty years, some excellent progress has been made in
understanding aspects of iron distribution and storage in the
brain. However, this is a highly multidisciplinary area, requir-
ing understanding of the biology, chemistry, and physics of
the sample preparation, measurement techniques, and research
question, in addition to appreciation of the neuroscience and
(patho)physiology. Our aim in writing this review has been not
only to showcase synchrotron insights into iron in neurodegener-
ative disorders, but also to provide a resource, through the cited
literature, for investigators to draw upon when they are designing
future synchrotron experiments.
Investigators often work with limited quantities of donated
tissue specimens, with restricted information about the archive
conditions or control over sample preparation. It is practical to
work with small volumes of material because a high degree of
sensitivity can be achieved with synchrotron experiments, but it
is important to ensure that samples are properly selected, charac-
terized, and matched in advance of the synchrotron experiment,
and that all reasonable steps are taken to protect the integrity of
the property being measured (e.g., avoiding steps that introduce
contamination or alter the oxidation or mineral state of the iron
being studied).
In the original XRF analysis of PD tissues by Earle, his concern
that potassium may have leached from the tissue during storage
(Earle, 1968) highlights a fundamental challenge in the analysis
of trace metals in tissues. Sample storage and preparation may
partially or completely alter the property to be analyzed, and
careful experiment design is required to evaluate and minimize
the scope for this. For example, ﬁxation by prolonged immer-
sion in a chemical solution such as formalin may be necessary
to preserve components of the tissue, but it can have a detri-
mental effect on metal ions of interest where they are mobilized
in ﬁxative, and the extent of leaching varies depending on many
factors including sample size, archival period, composition and
pH of the ﬁxing solution, and the bound states of the individ-
ual elements (ranging from tightly encapsulated within proteins
or mineral deposits, to labile ions within the tissue). These fac-
tors will also determine the extent to which relevant chemical and
mineral states are preserved. A consequence is that making com-
parisons between studies where some have used ﬁxed tissue, and
others have used fresh or frozen tissues, is not always viable. As
metal ions are bound in a myriad number of ways, their propen-
sity to migrate, to be washed out of samples, or altogether lost
from tissues, can be expected to vary signiﬁcantly depending on
the experiment protocol, the microstructure of the tissue, and
whether proportions of unbound or loosely bound metal ions
are inﬂuenced by the disease condition being studied. The extent
of iron leaching from archived chemically ﬁxed tissue might be
expected to depend on how strongly iron is bound in the tis-
sue, raising the interesting question as to whether iron in healthy
and diseased brains is equally prone to loss. We anticipate that
the loosely bound iron implicated in neurodegenerative disor-
ders (Kell, 2010) will be disproportionately lost in chemically ﬁxed
tissues.
Multi-modal imaging is especially valuable in addressing com-
plex questions, and the sensitive site-speciﬁc analysis that can be
performed in tissues with synchrotron techniques is of most value
when observations can be directly related to broader histological
ﬁndings in the same tissue. The non-destructive nature of comple-
mentary methods such as FTIR and SXRF are a great advantage,
permittingmulti-modal and repeated/multi-resolution analysis of
sample regions, and one of the great advantages of synchrotron
studies is the minimal sample preparation and handling required
for most experiments. For example, cells can be grown directly
onto the substrates to be imaged in air, and tissue may be cryo-
sectioned and dried onto suitable support media with no further
preparation other than to cover the section in a manner that
complies with local health and safety guidelines.
Sample substrates are of great importance, as measurement
sensitivity (such as in SXRF) precludes the use of standard micro-
scope slides which contain iron in quantities signiﬁcantly above
SXRFdetection limits. Slide coatings on any substrate can be prob-
lematic, as illustrated by Miller et al. (2006), unless they are of very
high purity. Synthetic quartz slides are a practical option for many
experiments if a rigid substrate is required. They do not permit
X-ray transmission data to be obtained, but their chemical resis-
tance facilitates subsequent histological staining. Thin polymeric
ﬁlms such as Ultralene® have been used for many experiments
due to their low scattering background, and they are especially
useful where both transmission and reﬂection data are required.
Silicon nitride membranes are a versatile alternative, particularly
for work with cultured cells, and facilitate multi-modal imaging
ranging from the hard X-ray region to the infra-red (Carter et al.,
2010).
CONCLUSION
In this review we have explored several ways in which syn-
chrotron techniques have contributed to our understanding of
iron and iron-binding metalloproteins in neurodegenerative dis-
orders. This has included neuromelanin in PD, Aβ in AD, and
the regional, cellular, and sub-cellular distribution of iron and
other elements in health and disease. There is untapped scope
to exploit synchrotron techniques in this ﬁeld, especially mul-
timodal analysis where complementary methods (such as FTIR
and SXRF) can obtain correlations between proteins, metabolites,
and elemental distributions at high spatial resolution. Analysis
of concentration change alone cannot usually explain mechnisms
or sufﬁciently inform treatment strategies, and insights into the
inorganic chemistry aspects of the “iron question” in neurodegen-
erative disorders may yet be provided by synchrotron techniques
that are still largely the preserve of chemists and physicists, such
as XMCD (Everett et al., 2014a). The majority of studies to date
have not included steps to preserve sample chemistry using cryo-
genic or anoxic conditions, but this may be necessary to address
fundamental questions in neurodegenerative disorders. Addition-
ally, many temporal aspects of iron trafﬁcking within cells and
tissues remain to be understood. The time-resolved experiments
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that can be achieved at synchrotrons may offer uniquely sensitive
non-destructive opportunities to investigate real-time processes in
living cells and tissues.
Synchrotron techniques offer tremendous potential to advance
our understanding of iron dysmetabolism in neurodegenerative
diseases, with unparalleled sensitivity, speciﬁcity, and temporal
resolution making it practical to work with tiny analyte volumes,
in highly dilute systems, performing unambigous speciation, and
gaining a measure of many properties in a single or combined
experiment at a given facility. The simplicity of the sample prepa-
ration techniques also offers excellent scope for complementary
imaging. For example, SXRF has advanced our understanding
of the relationship between iron and other elemental distribu-
tions in various regions of the brain in health and disease, and
permitted identiﬁcation of iron-rich structures in tissue so that
they might subsequently be analyzed to determine oxidation states
and biomineral form. Sub-cellular analysis has permitted direct
investigation of the relationship between iron, other metal ele-
ments, dopamine, and neuromelanin, whereas lower-resolution
spatial analysis has enabled direct correlation between iron maps
and magnetic resonance imaging parameters to assist in the
interpretation of clinical MRI measurement of brain iron.
Considering the work reported to date, the scale of which we
have sought to capture in this review, it is evident that while cer-
tain questions have been studied in detail, someneurodegenerative
disorders and/or brain regions have been largely overlooked, or
only analyzed by a sub-set of the synchrotron techniques avail-
able. With this opportunity to learn more about the role of iron
in neurodegenerative disorders, emphasis should be placed on
experiment design, given the limited access to synchrotrons and
to donations of human tissue for post-mortem analysis. This will
ensure that with the burgeoning opportunities and growing inter-
est in synchrotron research, carefully formed and precise questions
are addressed to ensure effective advancement of our understand-
ing of, and capacity to diagnose and treat, neurodegenerative
disorders.
LIST OF TERMS
The primary technical terms and acronyms used in this article
are summarized below. A broader overview of techniques and
terms is given in the review by McRae et al. (2009), and suggested
guidelines for terminology in this ﬁeld are provided elsewhere
(Lobinski et al., 2010).
FTIR Fourier transform infrared spectroscopy
(LA)ICP-MS (Laser-ablation) inductively coupled plasma
mass spectrometry
PIXE particle-induced X-ray emission
SAXS small Angle X-ray Scattering
SIMS secondary ion mass spectrometry
SXRF synchrotron X-ray ﬂuorescence
(E)XAFS (Extended) X-ray absorption ﬁne structure
XANES X-ray absorption near edge spectroscopy
XAS X-ray absorption spectroscopy
XCD X-ray Circular Dichroism
XMCD X-ray Magnetic Circular Dichroism
XSEM X-ray secondary-emission microscopy
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